Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy–associated TPM1 variants
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci179135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Saiti S Halder und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Tropomyosin, Cardiomyopathy, Dilated, Cardiomyopathy, Hypertrophic, Phenotype. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Science Foundation, National Institutes of Health.
Abstract (Originalsprache)
Heritable forms of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) represent starkly diverging clinical phenotypes, yet may be caused by mutations to the same sarcomeric protein. The precise mechanisms by which point mutations within the same gene bring about phenotypic diversity remain unclear. Our objective was to develop a mechanistic explanation of diverging phenotypes in two TPM1 mutations, E62Q (HCM) and E54K (DCM). Drawing on data from the literature and experiments with stem cell–derived cardiomyocytes expressing the TPM1 mutations of interest, we constructed computational simulations that provide plausible explanations of the distinct muscle contractility caused by each variant. In E62Q, increased calcium sensitivity and hypercontractility was explained most accurately by a reduction in effective molecular stiffness of tropomyosin and alterations in its interactions with the actin thin filament that favor the “closed” regulatory state. By contrast, the E54K mutation appeared to act via long-range allosteric interactions to increase the association rate of the C-terminal troponin I mobile domain to tropomyosin/actin. These mutation-linked molecular events produced diverging alterations in gene expression that can be observed in human engineered heart tissues. Modulators of myosin activity confirmed our proposed mechanisms by rescuing normal contractile behavior in accordance with predictions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Yale University, New Haven, Connecticut, USA.
- Department of Pharmacology, Physiology & Biophysics, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
- Department of Biological Sciences, University of Massachusetts Lowell, Lowell, Massachusetts, USA.
- Department of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Chicago, Illinois, USA.
Förderung
- NHLBI NIH HHS
- National Science Foundation
- National Institutes of Health
Zitieren
APA
Halder, S. S., Rynkiewicz, M. J., Kim, L., Barry, M. E., Zied, A. G., Sewanan, L. R., Kirk, J. A., Moore, J. R., Lehman, W. J., & Campbell, S. G. (2024). Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy–associated TPM1 variants. Journal of Clinical Investigation. https://doi.org/10.1172/jci179135
Vancouver
Halder SS, Rynkiewicz MJ, Kim L, Barry ME, Zied AG, Sewanan LR, et al. Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy–associated TPM1 variants. Journal of Clinical Investigation. 2024. doi:10.1172/jci179135
BibTeX
@article{Halder2024,
author = {Halder, Saiti S and Rynkiewicz, Michael J and Kim, Lynne and Barry, Meaghan E and Zied, Ahmed Ga and Sewanan, Lorenzo R and Kirk, Jonathan A and Moore, Jeffrey R and Lehman, William J and Campbell, Stuart G},
title = {Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy–associated TPM1 variants},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci179135}
}
EUVIMED